3-碘甲基-3-甲基氧杂环丁烷 | 112823-30-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧杂环丁烷
• 中文名称: 3-碘甲基-3-甲基氧杂环丁烷
• 中文别名: 3-甲基-3-碘甲基氧杂环丁烷
• 英文名称: 3-(iodomethyl)-3-methyloxetane
• CAS: 112823-30-0
• 化学式: C₅H₉IO
• mdl: MFCD11553032
• 分子量: 212.03
• InChiKey: UAYNHSVKPDQASH-UHFFFAOYSA-N

物化性质

• 沸点：
  72-75 °C(Press: 10 Torr)
• 密度：
  1.7437 g/cm3

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  7
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2932999099
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-(Iodomethyl)-3-methyloxetane
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-(Iodomethyl)-3-methyloxetane
CAS number: 112823-30-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C5H9IO
Molecular weight: 212.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen Iodide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-碘甲基-3-甲基氧杂环丁烷 在 水 、 sodium ethanolate 、 sodium chloride 作用下， 以 乙醇 、 二甲基亚砜 为溶剂， 反应 6.5h， 生成 ethyl 3-(3-methyloxetan-3-yl)propanoate
  参考文献：
  名称：

  Isomerization of cyclic ethers having a carbonyl functional group: new entries into different heterocyclic compounds

  摘要：

  Oxiranes (epoxides) and oxetanes having a carbonyl functional group are chemoselectively isomerized to different heterocyclic compounds via Lewis acid-promoted 1,6- and 1,7-intramolecular nucleophilic attacks of the carbonyl oxygen on the electron-deficient carbon neighboring the oxonium oxygen: for example, cyclic imides to bicyclic acetals, esters to bicyclic orthoesters, sec-amides to 4,5-dihydrooxazole or 5,6-dihydro-4H-1,3-oxazines, and tert-amides to bicyclic acetals or azetidines. The intramolecular attack of a 1,5-positioned carbonyl oxygen predominantly results in a propagating-end isomerization polymerization. On the other hand, cyclic ethers having a 1,8- or farther positioned carbonyl group undergo conventional ring-opening polymerization. A tetrahydrofuran (oxolane) ring does not open, even with a 1,6-positioned carbonyl group. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4020(02)00701-9
• 作为产物：
  描述：

  3-(氯甲基)-3-甲基氧杂环丁烷 在 sodium iodide 作用下， 以 丙酮 为溶剂， 生成 3-碘甲基-3-甲基氧杂环丁烷
  参考文献：
  名称：

  PHENYL-TETRAHYDROISOQUINOLINE DERIVATIVES

  摘要：

  这项发明提供了具有通式（I）的新化合物，其中R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、A和n如本文所述，包括这些化合物的组合物以及使用这些化合物的方法。

  公开号：

  US20130274287A1

文献信息

• PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE
  申请人：GENENTECH, INC.

  公开号：US20130079321A1

  公开（公告）日：2013-03-28

  Pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein X is thiazolyl, pyrazinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  Formula I中的吡唑-4-基杂环基-羧酰胺化合物，包括其立体异构体、几何异构体、互变异构体和药学上可接受的盐，其中X为噻唑基、吡啶基、吡啶基或嘧啶基，用于抑制Pim激酶，并用于治疗由Pim激酶介导的癌症等疾病。公开了使用Formula I化合物进行体外、原位和体内诊断、预防或治疗哺乳动物细胞中的这类疾病或相关病理条件的方法。
• Stereospecific Synthesis of <i>E</i>-Alkenes through Anti-Markovnikov Hydroalkylation of Terminal Alkynes
  作者：Avijit Hazra、Jason Chen、Gojko Lalic

  DOI：10.1021/jacs.9b04800

  日期：2019.8.14

  We have developed a method for stereospecific synthesis of E-alkenes from terminal alkynes and alkyl iodides. The hydroalkylation reaction is enabled by a cooperative action of copper and nickel catalysts and proceeds with excellent anti-Markovnikov selectivity. We demonstrate the broad scope of the reaction, which can be accomplished in the presence of esters, nitriles, aryl bromides, ethers, alkyl

  我们开发了一种从末端炔烃和烷基碘立体有择合成 E-烯烃的方法。加氢烷基化反应是通过铜和镍催化剂的协同作用实现的，并以优异的抗马尔科夫尼科夫选择性进行。我们展示了该反应的广泛范围，该反应可以在酯类、腈类、芳基溴化物、醚类、烷基氯、苯胺和各种含氮杂芳族化合物的存在下完成。机理研究提供的证据表明，铜催化剂通过氢铜作用活化炔烃，从而控制整个反应的区域选择性和非对映选择性。镍催化剂活化烷基碘并促进与烯基铜中间体的交叉偶联。
• [EN] NEW PHENYL-TETRAHYDROISOQUINOLINE DERIVATIVES<br/>[FR] NOUVEAUX DÉRIVÉS DE PHÉNYL-TÉTRAHYDROISOQUINOLINE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2013156423A1

  公开（公告）日：2013-10-24

  The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, A and n are as described herein, compositions including the compounds and methods of using the compounds.

  这项发明提供了具有通式（I）的新化合物，其中R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、A和n如本文所述，包括这些化合物的组合物以及使用这些化合物的方法。
• Harnessing Alkylpyridinium Salts as Electrophiles in Deaminative Alkyl–Alkyl Cross-Couplings
  作者：Shane Plunkett、Corey H. Basch、Samantha O. Santana、Mary P. Watson

  DOI：10.1021/jacs.9b00111

  日期：2019.2.13

  A Negishi cross-coupling of alkylpyridinium salts and alkylzinc halides has been developed. This is the first example of alkyl-alkyl bond formation via cross-coupling of an alkyl amine derivative with an unactivated alkyl group, and allows both primary and secondary alkylpyridinium salts to react with primary alkylzinc halides with high functional group tolerance. When combined with formation of the

  烷基吡啶鎓盐和烷基卤化锌的根岸交叉偶联已被开发出来。这是通过烷基胺衍生物与未活化的烷基交叉偶联形成烷基-烷基键的第一个例子，并且允许伯烷基吡啶鎓盐和仲烷基吡啶鎓盐与具有高官能团耐受性的伯烷基卤化锌反应。当与伯胺形成吡啶鎓盐相结合时，该方法能够将 NH2 基团非规范地转化为具有广泛官能团耐受性的各种烷基取代基。
• RAS INHIBITORS
  申请人：Revolution Medicines, Inc.

  公开号：US20210130326A1

  公开（公告）日：2021-05-06

  The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.

  该披露涉及大环化合物，以及能够抑制Ras蛋白质的药物组合物和蛋白质复合物，以及它们在治疗癌症中的用途。